HOW DOES NEXALIN ADVANCED THERAPY WORK?

As the most complex and dynamic organ in the human body, the brain has continually eluded any definitive scientific understanding. Largely due to the enigmatic nature of the brain, the exact mechanism by which Nexalin Advanced Therapy produces such positive results is not fully understood. Laboratory and clinical evidence suggest that Nexalin's patented electrical stimulation affects the hypothalamus and related brain structures to adapt and change the levels of neurochemicals including neuropeptides, neurotransmitters, and neuromodulators. The data support that the Nexalin electrical stimulation results in the endocrine outputs moving toward "normalization," specifically from the hypothalamic nuclei and associated brain structures. A key indicator of this is a significant clinical change in levels of enkephalins and beta-endorphins in the cerebral spinal fluid of Nexalin-treated subjects, as well as other neurochemicals like serotonin. The change in these neurochemicals is also apparent based on the responses noted by the patients after they receive Nexalin Advanced Therapy.

The hypothalamus' main function is to maintain homeostasis (a state of equilibrium) of the body. In order to perform this function, the hypothalamus constantly senses and adapts to information received by the brain. So, by nature the hypothalamus is sensitive and responsive to stimuli. Many disorders including anxiety, depression, and insomnia are believed to be a result of a decrease in the production of specific neurochemicals. Pharmaceutical therapies operate by replacing or inhibiting the uptake of these neurochemicals with a drug; Nexalin Therapy works by permitting your body to manage the production and uptake of these neurochemicals on its own. With its regimen of consecutive therapy sessions, Nexalin Therapy utilizes the hypothalamus' adaptive ability resulting in changes to the production of these neurochemicals to more normalized levels. The clinical effect is a decrease in the patient's symptoms. Clinical trial results confirm this.

The Nexalin Device has extensive clinical experience - the clinical trials have studied more than 700 subjects and provided more than 10,000 therapies. Nexalin Therapy has been and continues to be used in clinical studies involving a number of additional symptoms that arise from an imbalance in neurochemicals. The symptoms include those in patients with Parkinson's disease, chronic osteoarthritis pain, and post-surgical pain. Although the numbers of therapy sessions differ, the Nexalin Device's electrical stimulation has consistently shown positive results and statistically significant results in most cases. Furthermore, the improvements are clinically significant and lasting- typically for months- with no statistically significant drop off. We believe that this provides strong support for Nexalin Therapy's positive and durable effects on the hypothalamus and associated brain structures.

1 U.S. Patent #6904322B2

NEXALIN'S PATENTED WAVEFORM

The Nexalin device produces a patented waveform that provides transcranial electrical stimulation (TES). In clinical trials, this unique waveform resulted in the greatest increase in beta-endorphins. The Nexalin device has undergone extensive safety analysis with the results clearly indicating that the device is safe for its intended use. Additionally, the FDA classification of the device for clinical trials places it into a non-significant risk (low risk device) category.

HOW IS THE THERAPY ADMINISTERED?

The patented waveform of Nexalin Advanced Therapy is administered through medical grade conductive pads that are produced specifically for the Nexalin technology.  The pads are placed on the forehead and behind each ear, and are connected to the Nexalin device with thin cables.

Nexalin Advanced Therapy is a highly effective, yet soothing treatment. Most patients feel nothing during Nexalin Therapy. At Nexalin Advanced Therapy Centers, patients are treated to a quiet, 40-minute session where many actually relax to the point of sleep during a session. Relief starts as early as the first therapy and most experience relief by the third session.

CONCLUSION

Nexalin Therapy provides stimulation that appears to affect the hypothalamus and associated brain structures to adapt and alter the levels of neuropeptides, neurotransmitters, and neuromodulators critical to maintaining normal mood behavior. This effect is long lasting. It is hypothesized that with the right maintenance program, normalization can be maintained for prolonged periods. This is the program we offer at the Nexalin Advanced Therapy Centers.

The other important factor is that at the completion of the Nexalin Therapy the hypothalamus has either adapted to a new level and stabilized or is in the process of stabilizing, resulting in the long lasting benefit.